Clinical Trials Logo

Bone Neoplasms clinical trials

View clinical trials related to Bone Neoplasms.

Filter by:

NCT ID: NCT05406063 Recruiting - Pain Clinical Trials

Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases

SMILE
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

To investigate, whether multi-fraction stereotactic body radiation therapy (SBRT) within 3 treatment fractions is non-inferior to the current standard of care of 5 fraction SBRT regarding pain response at 3 months after radiotherapy.

NCT ID: NCT05395741 Recruiting - Osteosarcoma Clinical Trials

Regorafenib in Patients With Refractory Primary Bone Tumors

Regbone
Start date: April 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options using advanced molecular diagnostics for patients who have not responded to the standard therapeutic regimen, and to introduce modern diagnostics for risk stratification and for the use in molecularly targeted therapies.

NCT ID: NCT05310539 Recruiting - Bone Neoplasm Clinical Trials

Early Recovery After "Wedge Resection" Surgery to Remove Lung Mestastasis Secondary to Bone Cancer.

Start date: January 8, 2022
Phase:
Study type: Observational

After "wedge resection" surgery, the physiotherapy programs proposed in the literature are heterogeneous and there are few data on the outcomes of such treatments in an oncological population for bone cancer. The aim of the study is to describe the early rehabilitation process after wedge resection surgery secondary to bone tumor pulmonary mestasasis, highlightining the possible functional recovery in the short and medium term after surgery and indentifying the possible prognostic factors.

NCT ID: NCT05241132 Recruiting - Chemotherapy Effect Clinical Trials

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Start date: November 12, 2021
Phase: Phase 2
Study type: Interventional

Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy (platinum + paclitaxel) in the treatment of patients with bone metastases cancer with unknown primary, and provide a better treatment plan for these patients. 1. Primary outcome: Objective response rate (ORR) 2. Secondary outcomes: disease control rate (DCR), duration of remission (DOR), progression-free disease (PFS), overall survival (OS), median PFS, median OS, stratification based on clinical features and PD-L1 expression, adverse reactions (AEs), and quality of life.

NCT ID: NCT05179824 Recruiting - Breast Cancer Clinical Trials

Tempus Priority Study: A Pan-tumor Observational Study

Start date: October 19, 2020
Phase:
Study type: Observational

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

NCT ID: NCT05167669 Recruiting - Pain Clinical Trials

Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU

BM-RT-HIFU
Start date: October 1, 2022
Phase: Early Phase 1
Study type: Interventional

Metastatic disease to the bone is a common cause of pain. External beam radiation therapy (EBRT) is the standard palliative treatment BUT pain improvement is observed in 60% to 80%. Combination of hyperthermia (HT) with radiation is strongly compelling. MR is providing accurate, tissue-independent thermometry for intra-procedural guidance of thermal therapy. In this project we aim to combine in an adjuvant setting mild hyperthermia to EBRT for sustained relief of pain in patients with symptomatic bone metastases.

NCT ID: NCT05108298 Recruiting - Melanoma Clinical Trials

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Start date: November 10, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

NCT ID: NCT05071001 Recruiting - Clinical trials for Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)

Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence

OSE
Start date: March 19, 2021
Phase: N/A
Study type: Interventional

To assess the neurocognitive outcomes in patients treated with chemotherapy for a malignant bone tumor during childhood and adolescence and the factors associated with neurocognitive impairment and/or complaints

NCT ID: NCT05058014 Recruiting - Clinical trials for Metastatic Bone Tumor

Skeletal Metastasis Registry

Start date: August 16, 2018
Phase:
Study type: Observational [Patient Registry]

This is a prospective, observational study designed to contribute data from patients with symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information from patients treated for symptomatic bone metastases within the International Skeletal Metastasis Registry (ISMR)

NCT ID: NCT05057143 Recruiting - Surgery Clinical Trials

3D Printed Implants for the Defect Reconstruction in Patients With Chest Wall Tumors

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

A patient with a tumor lesion of the chest wall undergoes CT scan with a step width of less than 1 mm, then engineers design an individual model to replace the defect. Using a 3D printer, a model is made based on titanium alloy powder. Preoperative preparation takes an average of 14-21 days. The next stage is surgical treatment in the amount of resection of the chest wall with plastic defect with an individual titanium implant. In some cases, the titanium framework is separated from the pleural cavity by a polytetrafluoroethylene plate in order to seal and prevent the development of pulmonary hernias. The advantages of titanium individual prostheses include accurate matching of the implant to the size and characteristics of the defect, individual modeling allows you to repeat the anatomical features of the patient. This method helps to recreate the original shape of the chest, and most importantly, symmetrical, relatively healthy half. With the help of titanium, individualized prostheses are made based on 3D modeling, which will reduce the incidence of complications, accelerate rehabilitation and improve the quality of life of patients with tumor lesions of the chest wall. The postoperative period takes 15-30 days.